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ABSTRACT 
We located a comprehensive sample of studies (1980–1999) on the psychosocial and 
pharmacological treatment of child and adolescent depression through an extensive literature 
search. Articles that met the inclusionary criteria were subsequently analyzed. The outcome data 
from 38 studies were extracted and converted into effect sizes (ESs). Comparisons of main 
effects, demographic, and quality of study variables were conducted. The overall findings of this 
meta-analysis indicate that several different psychosocial interventions for child and adolescent 
depression produced moderate to large treatment gains that were clinically meaningful for many 
afflicted youth. However, in general, the vast majority of pharmacological interventions were not 
effective in treating depressed children and adolescents. Nonetheless, there is recent evidence 
that selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are efficacious, and will 
likely play an increased role in the management of affective illness in youngsters. The clinical 
implications and limitations of these data are discussed and suggestions for future research are 
provided. 
 
 
 
 
ARTICLE 
1. Introduction 
Although childhood depression was not a recognized phenomenon until recently, it is now 
considered to be an important area of research in child psychopathology (e.g., Cytryn; Kovacs 
and Kovacs). Estimates of the prevalence of child and adolescent depression in the general 
population are substantial, ranging from 0.4% to 8.3% (Birmaher; Fleming and Lewinsohn). 
Furthermore, there are a number of negative outcomes associated with child and adolescent 
depression including: diminished self-esteem (Kazdin, 1988), poor physical health (Costello et 
al., 1988), family dysfunction (Kashani, Burbach, & Rosenburg, 1988), increased risk for 
substance abuse (Kovacs, Goldston, & Gatsonis, 1993), disrupted parent–child attachment 
(Kovacs, 1997), and a substantial risk for morbidity and mortality across the lifespan (Fleming 
and Harrington). There is also compelling evidence that children and adolescents who suffer 
from depression have a variety of problems in daily living such as unsatisfying and conflicted 
interpersonal relationships (Puig-Antich et al., 1985), noteworthy declines in academic 
performance (Fleming, Offord, & Boyle, 1989), and an increased risk for dropping out of school 
(Fleming & Offord, 1990). Another reason to be concerned about child and adolescent 
depression is the association between clinical mood disturbances and suicide (Kovacs and Rao). 
 
Moreover, childhood depression is often persistent and leads to an increased risk of recurrence 
during adolescence and adulthood (Kovacs, Obrosky, Gatsonis, & Richards, 1997). In a number 
of investigations, up to 40% of the children originally identified with depressive symptoms 
remained symptomatic years later (e.g., DuBois; Fleming; Kovacs; Lewinsohn and Nolen). In 
summary, the data regarding the prevalence, negative outcomes, and persistence of child and 
adolescent depression offer ample justification for providing effective treatments early during the 
course of the illness. Indeed, several researchers and clinicians have developed and implemented 
various treatments for child and adolescent depression ranging from psychosocial interventions 
to pharmacological regimens. Thus, the purpose of the present investigation is to systematically 
review the overall effectiveness of psychosocial and pharmacological treatments for child and 
adolescent depression. 
 
 
1.1. Review of reviews 
 
1.1.1. Psychosocial treatment 
Many of the attempts to synthesize the literature on the treatment of child and adolescent 
depression have been narrative in nature. For example, with respect to psychosocial 
interventions, a total of 13 narrative reviews were located, published between 1983 and 1998 
(e.g., Birmaher; Cytryn; Kashani and Kaslow, N.J. and Thompson, M.P., 1998. Applying the 
criteria for empirically supported treatment to studies of psychosocial interventions for child and 
adolescent depression. Journal of Clinical Child Psychology 27, pp. 146–155. Full Text via 
CrossRef | View Record in Scopus | Cited By in Scopus (101)Kaslow). Unfortunately, the 
number of psychosocial treatment studies cited in the above-mentioned reviews were often 
small, and noninclusive, ranging from zero (Cytryn & McKnew, 1985) to 14 (Kaslow & 
Thompson, 1998). In terms of the substantive findings from the earlier reviews, they are often 
unclear and conflicting, and did not consider how outcomes covaried with theoretically 
important demographic variables (e.g., age). In perhaps the most systematic narrative review to 
date, Kaslow and Thompson (1998, p. 146) reviewed 14 psychosocial interventions for child and 
adolescent depression. In general, the authors suggested that “psychosocial interventions are 
effective at posttreatment and follow-up in reducing depressive symptoms/disorders in clinical 
and nonclinical samples of youth, regardless of treatment modality or extent of parental 
involvement.” 
 
Although the overall efficacy of psychotherapy with children and adolescents has been examined 
via large meta-analytic reviews (Casey; Kazdin and Weisz), none of these investigators 
specifically addressed the issue of treating child and adolescent depressive disorders or they 
collapsed “depression” studies into more broadly defined categories (e.g., internalizing, 
emotional problems), making the extraction of specific data regarding the efficacy of depression 
treatment problematic. Only one large published meta-analytic review was located that addressed 
the issue of treating child and adolescent depression. In a meta-analytic review of 150 outcome 
studies on child and adolescent psychotherapy, Weisz, Weiss, Han, Granger and Morton (1995) 
included six controlled outcome studies of child and adolescent depression and reported a 
standard mean difference effect size (ES) of 0.64. 
 
In a more recent investigation, Reinecke, Ryan, and DuBois (1998) analyzed many of the same 
studies (i.e., four of the six) included by Weisz et al. (1995) and included two others (i.e., Lerner 
and Wood) in a highly focused meta-analytic review of controlled cognitive–behavioral 
interventions for depressed adolescents. Reinecke et al. (1998) reported a standard mean 
difference ES of 1.02. Although the findings from these investigations are important, Weisz et al. 
included only six studies and they did not specifically address how the outcomes of child 
depression studies might covary or interact with other variables (e.g., age, sex). In terms of the 
meta-analytic review by Reinecke et al., the sample of studies analyzed were not only similar to 
a previously published meta-analysis, but the findings were limited in that only cognitive–
behavioral interventions for adolescents were included. 
 
In one other meta-analytic review, Black-Cecchini (1996) analyzed 13 outcome studies 
investigating the efficacy of group-based social skills interventions for depressed youth as part of 
an unpublished doctoral dissertation. Black-Cecchini reported that the social skills group 
interventions produced moderate to large effects (i.e., average ES 0.76) in terms of ameliorating 
depressive symptomatology in depressed children and adolescents primarily from school 
samples. In addition, Black-Cecchini found that “inferior” studies had the highest mean ESs 
when compared to the higher quality studies. In summary, the existing narrative and meta-
analytic reviews of psychosocial depression treatments have provided clinicians and researchers 
with some important trends. However, to date, there has not been an attempt to collect and 
systematically compare a more comprehensive sample of depression treatment studies, including 
pharmacological interventions. Further, there is a need to examine whether there is differential 
effectiveness when other variables are taken into account (e.g., age). 
 
 
1.1.2. Pharmacological treatment 
The prescription of psychotropic medications for children and adolescents has become a widely 
accepted practice (Kaplan, Simms, & Busner, 1994) despite the fact that the Food and Drug 
Administration (FDA) has yet to approve a single psychotropic agent for the specific purpose of 
treating depressed youth up to the age of 17 years old ( Physician's Desk Reference, 1999; Peter 
Jensen, personal communication, March 16, 1998; Sommers-Flanagan & Sommers-Flanagan, 
1996). Moreover, the potential adverse impact that pharmacological interventions have on child 
development remains unclear (Antonuccio and Vitiello). There have also been some serious 
concerns raised about treating children with tricyclic antidepressants (TCAs) because of 
potentially noxious or lethal side effects (e.g., Riddle; Werry and Wilens). However, given the 
advent of selective serotonin reuptake inhibitors (SSRIs), which are known to have less noxious 
side effect profiles (e.g., limited anticholinergic and sedative effects) and are easier to administer 
(i.e., once per day) than most of the TCAs, a number of practitioners have opted to use these 
medications as a safer alternative to the TCAs for the treatment of child and adolescent 
depressive disorders (Birmaher et al., 1996). 
 
Despite the aforementioned concerns, a number of controlled medication trials for child and 
adolescent depression have been conducted. In the only published meta-analytic review located, 
Hazell, O'Connell, Heathcote, Robertson, and Henry (1995) analyzed 12 randomized, controlled 
trials comparing the efficacy of TCAs and placebo in depressed children between 6 and 18 years 
of age. The authors reported a standard mean difference ES of 0.35 for the active medication 
conditions vs. the placebo (control) conditions. Hazell et al. (1995, p. 899) concluded that “the 
small additional effect afforded by treatment in comparison with placebo is unlikely to be 
clinically important in most patients.” However, according to the authors, they were only able to 
derive ESs from 6 of the 12 studies due to limited information contained in the articles. Thus, 
some authors have criticized the conclusions from this meta-analytic review on empirical 
grounds (e.g., Anderson, 1995). Furthermore, in a review of the drug trials for early-onset 
depression, Conners (1992, p. 11) cautioned that “various methodological problems limit the 
conclusions that can be drawn” regarding the efficacy of antidepressant medications. That is, the 
substantial differences in the measurements used, criteria for “improvement,” selection 
procedures, and sample characteristics in the various studies render comparisons across the 
studies tenuous at best (Conners, 1992). 
 
Overall, it is estimated that there are between 14 and 17 published studies investigating the 
efficacy of psychotropic medications (i.e., TCAs and SSRIs) for depressed youth. A more up-to-
date meta-analytic review that integrates the recent studies (especially those in which SSRIs 
were used), and includes a systematic examination of some of the important variables associated 
with outcome might provide some answers to important questions related to the effectiveness of 
pharmacotherapy for child and adolescent depression. Furthermore, there is a paucity of data on 
the comparison of pharmacological and psychosocial interventions for depressed children and 
adolescents. Only one study was located that compared psychotherapy vs. pharmacotherapy in 
the treatment of early-onset depression. Dujovne (1993) treated six clinically depressed children 
between 8 and 11 years old with imipramine and cognitive–behavioral therapy in a multiple-
baseline, crossover design. Dujovne reported that both treatments resulted in a significant 
reduction in depressive symptoms over the course of the study with a slight advantage to the 
cognitive–behavioral regimen and increased parental satisfaction of the nonpharmacological 
intervention (i.e., cognitive–behavioral therapy). Thus, it appears that several important 
questions remain regarding the comparison of psychosocial and pharmacological treatments for 
depressed youth. And while direct comparisons between the psychotherapy and 
pharmacotherapy are well beyond the scope of this study, a meta-analytic review of both 
literature bases within the same investigation may serve a useful purpose for clinicians and 
practitioners who are interested in a comprehensive snapshot of treatment outcomes for 
depressed children and adolescents. 
 
 
1.2. Interaction of variables 
 
1.2.1. Age 
Several previously unconsidered variables may have an important impact on treatment outcomes 
include age, sex, and quality of study. No published studies were located that specifically 
addressed the potential interaction between age and the treatment of early-onset depression, i.e., 
adolescent vs. child samples. (For purposes of clarity, children are referred to as those who are 
between 6 and 12 years old, whereas adolescents are identified as those who are between the 
ages of 13 and 18). 
 
The empirical findings on the relationship between a child's age and general psychotherapy 
outcome have been equivocal. For example, Weisz et al. (1987, p. 542) reported “therapy proved 
more effective for children (ages 4–12) than for adolescents (ages 13–18).” In contrast, Weisz et 
al. (1995, p. 461) completed another integrative review (150 different studies) of the effects of 
psychotherapy with children and adolescents and reported that “treatment outcomes were better 
for adolescents than for children.” For children 11 and younger, the authors reported a mean ES 
of 0.48, whereas the mean ES was 0.65 for adolescents 12 and older. Thus, the relationship 
between age and outcome remains unclear, especially with respect to the treatment of child and 
adolescent depression. 
 
1.2.2. Sex 
The interaction between sex and treatment outcome has been investigated by several researchers 
who have conducted large meta-analytic reviews (e.g., Casey and Weisz). Taken together, the 
findings suggest that psychotherapy is generally more effective for females than males. Weisz et 
al. (1987) reported a mean ES of 1.11 for female majority groups and 0.80 for male majority 
groups. Weisz et al. (1995) reported similar findings, indicating that the mean ES for female 
majority samples was 0.71 as compared to 0.43 for male majority samples. In addition, the 
authors reported an Age×Sex interaction wherein the mean ES was 0.86 for adolescent female 
majority samples as compared to 0.37 for adolescent males. In contrast, the mean ESs for the 
male and female child samples (i.e., 11 and younger) were approximately equal. Thus, while 
there have been some interesting findings to date, more information is needed to better 
understand the relationship between sex and depression treatment outcome. 
 
1.2.3. Quality of study 
Various authors have suggested that the quality of a study can impact not only the findings from 
a particular study, but also the overall findings from an integration or meta-analytic review of 
several studies (e.g., Wilson and Wortman). Weiss and Weisz (1990, p. 639) examined the 
results from large meta-analytic studies to determine whether methodological factors impacted 
the magnitude of ESs. These researchers reported that “in general, increased experimental rigor 
was related to larger effect sizes.” To add to this literature base, the quality of each psychosocial 
study included in the present analysis will be coded and evaluated to examine whether 
methodological factors impacted treatment outcome. Evaluating the quality of the 
pharmacological studies was not feasible, given the insufficient data contained within the articles 
to render a reasonable methodological assessment. 
 
In summary, there are three primary questions that will be addressed in the current investigation. 
First, what is the overall effectiveness of psychosocial interventions for child and adolescent 
depression? Second, what is the overall effectiveness of pharmacological treatments for child 
and adolescent depression? Third, is there evidence of differential effectiveness for psychosocial 
and pharmacological treatments when age, sex, and quality of study are considered? 
 
 
2. Method 
 
2.1. Population and sample 
The population for this investigation included empirical studies on the treatment of child and 
adolescent depression. The overall sample for this investigation included 38 psychosocial and 
pharmacological studies targeting child and adolescent depression published between 1980 and 
1999. There were 24 psychosocial studies (38 separate treatments) and 14 pharmacological trials. 
Case reports and single-subject designs were not included. Of the 24 psychosocial trials, the 
majority (15/24; 63%) were between-subject studies with wait-list, placebo, or no-treatment 
control groups and included mostly nonreferred youngsters (13/15; 87%) with depressive 
symptoms who were treated predominantly in school-based group interventions. For a between-
group study to be considered a controlled trial, random assignment to one of the various 
conditions was a requirement. The remaining nine psychosocial trials were pre/post studies, 
seven (78%) of which included clinically referred youngsters with depressive diagnoses who 
were treated predominantly in outpatient clinical settings. In essence, the majority of the 
controlled trials were “efficacy” studies (i.e., mostly recruited subjects treated in school-based 
settings) whereas most of the pre/post trials were “effectiveness” studies conducted primarily in 
naturalistic clinic settings with referred subjects (see Hoagwood, Hibbs, Brent, & Jensen, 1995, 
for a clarification of the distinction between efficacy and effectiveness research). All of the 14 
pharmacological studies were controlled trials with children who met diagnostic criteria for 
Major Depressive Disorder. The articles were located through a comprehensive search strategy 
including an extensive computer search of databases such as PsycLIT, ERIC, and Medline. Hand 
searches of the reference lists from the obtained articles were conducted in an effort to find 
additional articles and several authors were contacted to inquire about “in press” studies or 
unpublished manuscripts. Manual searches of a variety of peer-reviewed journals were 
completed as well, including but not limited to: the Journal of Consulting and Clinical 
Psychology, the Journal of the American Academy of Child and Adolescent Psychiatry, 
Behavior Therapy, Archives of General Psychiatry, School Psychology Review, Behavioral 
Psychotherapy, the Journal of Abnormal Child Psychology, the Journal of Clinical Child 
Psychology, and the Journal of Affective Disorders. 
 
Finally, a comprehensive search of unpublished theses and dissertations via ProQuest 
Dissertation Abstracts was completed dating back to 1980. A total of 10 potentially relevant 
dissertations were located, all of which were ordered. Several of the dissertations ordered were 
not received (i.e., four) due to restrictive lending policies at the various institutions. Of the six 
dissertations received, two were deemed appropriate for coding and included in the final sample 
of studies. 
 
For a study to be included in the investigation, the effects of a particular treatment on child and 
adolescent depression had to be examined. The following specific criteria must have been met as 
well: the study had to be a within- or between-subjects group design; the sample was targeted for 
intervention based upon “at-risk” status (i.e., secondary prevention), presenting depressive 
symptomatology, or a depressive diagnosis; the subjects targeted for intervention were between 
the ages of 5 and 18; the treatment was psychosocial or pharmacological in nature (e.g., group, 
individual, family, TCA, SSRI); and at least one depression outcome measure was administered 
once the intervention was completed. 
 
2.2. Design and analysis 
An integrative or meta-analytic design was used during the course of this study, whereby the 
results from related treatment studies are compared (Glass, 1977). In the present study, a 
standardized mean difference ES was calculated (Smith, Glass, & Miller, 1980). A 
comprehensive coding sheet was developed so that each of the treatment outcome studies was 
evaluated based on the identified variables (e.g., age, sex). The quality of each study was rated 
based on: (a) potential threats to internal validity, and (b) the overall validity of the study. The 
potential threats included: maturation, history, testing, instrumentation, regression, selection bias, 
and experimental mortality. These threats to internal validity and the associated effects upon 
treatment outcomes have been described extensively in the literature (e.g., Campbell & Stanley, 
1963). All of the aforementioned threats were evaluated based on a 0–3 scale (0=not a plausible 
threat; 1=minor threat; 2=plausible threat; 3=by itself could explain the findings), and these data 
were combined with an assessment of other methodological factors (i.e., sample size, selection 
procedures, methodological rigor, and measurement technology) to yield an overall score. A 
five-point Likert scale (5=excellent; 4=good; 3=fair; 2=inferior; 1=unacceptable) was used to 
evaluate the overall quality of each study. 
 
All treatment studies were double-coded by the primary researcher and a PhD candidate in 
psychology, who underwent extensive training in specific coding procedures. Two formulas 
were used to calculate the interrater agreement. First, interrater agreement percentages were 
calculated by dividing the total number of congruent observations (CO) by the total number of 
observations (TO) and multiplied times 100. Second, Cohen's Kappa (Cohen, 1960) was 
calculated for each variable to compensate for the limitations in the first formula. Interrater 
agreement rates ranged from 88% to 100% with an average agreement of 95.3%. Kappa 
coefficients ranged from .76 to 1.00, with an average kappa reliability coefficient of .91. The 
kappa coefficients for the specific variables under study in the present investigation were 1.00 
(age), .92 (percent female), and .76 (overall quality of study). Disagreements in the coding of any 
variables were reconciled through consultation and clarification among the coders. 
 
The results and variables from the various treatment studies were analyzed by computing a 
number of ESs. The calculation of ESs for the psychosocial studies were based upon measures of 
depressive symptoms and depressive diagnoses (i.e., self-report measures, diagnostic interviews). 
In some cases, the investigators used more than one self-report measure or combined self-report 
data with interview findings. Of the 24 psychosocial studies, 9 used a single self-report measure 
to assess outcome, while 3 studies combined 2 self-report measures to determine outcome. The 
remaining 12 studies used a combination of self-report and interview data to assess outcome. In 
studies where more that one assessment device was included, the measures were collapsed to 
yield one overall ES for each study to avoid the potential limitation of unequal weighting of 
studies with multiple ESs (Glass, 1977). 
 
ESs were calculated with the assistance of the DSTAT computer software program (Johnson, 
1989) whereby the outcome data (i.e., means, standard deviations, sample sizes) were entered. In 
cases where the means and standard deviations were not provided, ESs were computed from 
other data reported in the studies (e.g., F ratios or t statistics). Furthermore, in a large number of 
pharmacological studies, means, standard deviations, F ratios, or t statistics were not reported. 
Instead, the percentage of improvement in the treatment and placebo-control groups was 
reported. Treatment response in these studies was determined by whether the subjects met 
criteria for “improvement” (i.e., change observed on particular measures). However, the criteria 
for improvement and the measures utilized to determine change varied across the studies. 
Nonetheless, ES estimates were calculated by transforming the difference in proportions (percent 
improved) between the experimental and placebo-control group subjects. This procedure (probit 
transformation) has been used in a number of meta-analyses (e.g., Clum and Miller, 1977) and is 
described elsewhere (see Smith et al., 1980). 
 
Although this procedure is far from ideal in calculating ESs, it is more effective and accurate 
than simply excluding the study from the analysis. One of the primary limitations of this 
procedure is the inevitable loss of information that takes place after the outcome data are 
transformed multiple times into an ES. Nonetheless, it addresses a criticism (Anderson, 1995) of 
a previous meta-analysis (Hazell et al., 1995) on the efficacy of using antidepressant medications 
in children and adolescents whereby ESs were calculated from only 6 of the 12 studies due to the 
limited data contained in the articles. For studies that did not report any data suitable for 
conversion to ESs, but were important to include in the final analysis to increase 
comprehensiveness (and to reduce selection bias), an ES estimate of zero was entered. Assigning 
an ES of zero is a conservative procedure designed to prevent an inflated overall ES estimate, 
when including important, albeit incomplete information from particular studies (Rosenthal, 
1984). In the present study, an ES of zero was entered only when the data could not be converted 
to an ES and the authors reported nonsignificant differences between the active and placebo 
conditions. An ES of zero was entered for three of the pharmacological studies that reported 
nonsignificant differences between the active vs. the placebo conditions and the data in the 
articles were insufficient to compute ESs. 
 
For between-subjects group designs, the traditional meta-analytic formula, first proposed by 
Glass (1977), was utilized whereby unweighted ESs are calculated by subtracting the control 
group mean from the treatment group mean, divided by the control group (Glass, 1977). 
However, in order to get the best and most stable estimate of the variance of untreated subjects, a 
pooled standard deviation was used as the denominator, wherein the standard deviations of the 
experimental and control groups at pretreatment and the posttreatment S.D. of the control group 
only were combined (see Cohen's D; Cohen, 1988). Thus, in every case, the computed ESs were 
based on the variance estimates of untreated subjects. For within-subjects group designs, 
unweighted ESs were calculated as well. However, in these studies, the ES was interpreted as the 
magnitude of change observed in the experimental group from the pretreatment to posttreatment 
phases (i.e., intrasubject variance). As such, comparisons of within- and between-group ESs 
were inappropriate. However, pre/post ESs were calculated for the between-group designs to 
facilitate a useful comparison of treatments across the two designs. 
 
 
3. Results 
 
3.1. Descriptive statistics 
A summary of the descriptive data for the reviewed psychosocial and pharmacological studies is 
presented in Table 1. As can be seen, the majority of psychosocial trials (15/24; 63%) were 
between-subject studies with wait-list, placebo, or no-treatment control groups and included 
mostly nonreferred youngsters with depressive symptoms who were treated predominantly in 
school-based group interventions. The remaining nine psychosocial trials were pre/post studies, 
seven of which included clinically referred youngsters with depressive diagnoses who were 
treated predominantly in outpatient clinical settings. The psychosocial studies were published or 
conducted between 1980 and 1999, with the vast majority of studies published after 1990 (i.e., 
88%). There were 38 active treatments across all studies and 2 attention-placebo conditions. The 
modal treatment regimen was cognitive–behavioral group therapy (n=13), followed by 
nondirective, supportive individual therapy (n=3), social skills group therapy (n=3), cognitive–
behavioral individual therapy (n=4), and relaxation group therapy (n=2). The remaining 
treatments included nondirective, supportive group therapy, residential treatment, behavioral 
group therapy, aerobic exercise, individual relaxation therapy, role playing, family therapy, 
interpersonal therapy, and various combinations (e.g., group CBT plus parent group or group 
CBT plus family therapy). There were 3 prevention studies, 11 studies in which the subjects 
were targeted based on depressive symptomatology, and 10 studies where the subjects were 
included based on a depressive diagnosis (i.e., Major Depressive Disorder and/or Dysthymic 
Disorder). 
 
 
 
Table 1. Frequency and percentage of study characteristics 
 
In the between-subject group studies, there were a total of 1108 subjects between the ages of 7 
and 18 years old. The number of subjects in each of the controlled studies ranged from 7 to 152 
(median=57.5). There were six (40%) controlled studies in which the average age of the subjects 
was above 13 years old, whereas nine (60%) studies included subjects with a mean age of below 
13 years old. In the within-subject group designs, there were a total of 391 subjects between the 
ages of 5 and 18 years old. The number of subjects in each of the pre/post studies ranged from 8 
to 107 (median=46). Of the nine pre/post studies, 6 (66%) included subjects with an average age 
above 13 years old, whereas three (33%) studies included subjects with a mean age below 13 
years old. The average percentage of female subjects across all 23 studies was approximately 
56%. However, only 3 of the 24 studies (12.5%) reported separate findings based on sex. 
 
The number of therapy sessions in the controlled trials ranged from 8 to 27 (median=10.5) and 
the number of weeks for each treatment ranged from 2 to 12 weeks (median=8). The number of 
sessions in the pre/post studies ranged from 5 to 36 (median=11) and the number of weeks for 
each treatment ranged from 4 to 24 weeks (median=12). Of the 15 controlled studies, 10 (66%) 
included follow-up data, ranging from 1 month to 2 years posttreatment (median=7 weeks). 
Among the nine pre/post trials, five (55%) included follow-up data, ranging from 1 month to 1 
year posttreatment (median=4 months). 
 
All 14 pharmacological studies included in the analysis were controlled clinical trials with active 
medication and placebo conditions. All 14 studies included subjects based on a diagnosis of 
Major Depressive Disorder based on DSM criteria and information solicited from self-report 
measures, interviews, and observations. The pharmacological trials were published or conducted 
between 1981 and 1997 and 64% of studies were published after 1990. There were a total of 441 
subjects between the ages of 6 and 19 years old. The number of subjects in each of the 
pharmacological trials ranged from 6 to 96 (median=30). There were seven (50%) studies in 
which the subjects were 12 years of age or younger, six (43%) studies in which the subjects were 
13 years of age or older, and one (7%) study in which there were children and adolescents 
ranging from 7 to 17 years old (Emslie et al., 1997). The average percentage of female subjects 
across all pharmacological studies was approximately 42%. However, none of studies reported 
separate findings based on sex. 
 
The types of medications used in the pharmacological trials included imipramine (Tofranil; n=4), 
amitriptyline (Elavil; n=3), desipramine (Norpramin; n=2), nortriptyline (Pamelor; n=2), 
fluoxetine (Prozac; n=2), and venlafaxine (Effexor; n=1). The number of weeks for each 
treatment ranged from 4 to 8 weeks (median=6). The outcome data in the pharmacological trials 
were reported at the end of the acute phase of pharmacotherapy (i.e., posttreatment). Follow-up 
data were not included in the original articles. 
 
 
3.2. Main effects: psychosocial studies 
Summary data for the psychosocial studies are presented in Table 2. The overall mean difference 
ES at posttreatment was 0.72 (range=0.03–1.84; 95% CI 0.48–0.94). Of the eight controlled 
psychosocial studies that reported follow-up data (median=6.5 weeks), the mean ES was 0.64 
(range=0.08–1.55; 95% CI 0.32–0.95). 
 
Table 2. Overall mean effect sizes at posttreatment and follow-up 
Parenthetical ES values reflect amount of change on the dependent measures that were observed 
in controlled studies using intrasubject (pre/post) variance estimates; the ES value of 0.19 for 
pharmacological trials includes the addition of three ES estimates of zero from studies that 
reported “nonsignificant” differences between active and placebo conditions, but did not include 
sufficient data to compute an ES. 
 
 
 
With regard to the nine pre/post psychosocial studies, the overall mean ES at posttreatment was 
1.14 (range=0.23–2.30; 95% CI 0.75–1.52). For the five studies that reported follow-up data, the 
mean ES at follow-up (median=36 weeks) was 1.26 (range 0.95–1.94; 95% CI 0.99–1.52). 
 
In order to facilitate a useful comparison of the mean ES of the between- and within-subject 
group designs, pre/post ES were also calculated for the controlled studies. The overall mean ES 
for controlled studies using intrasubject variance estimates was 1.23 (range=0.30–2.27; 95% CI 
0.90–1.55), which was comparable with the average ES for the pre/post studies (i.e., ES=1.14). 
To gather an understanding of the amount of change that occurred without treatment, pre/post 
ESs were calculated for control group subjects only. The pre/post ES calculations for control 
group subjects yielded a mean ES of 0.37 averaged across the 15 studies. These data 
approximate the amount of change between the pretreatment and posttreatment phases that could 
not be explained by or attributed to the therapeutic interventions themselves. 
 
In general, the positive main effects of the 38 psychosocial treatments (across 24 studies) 
remained strong even when the type and severity of depressive illness was taken into account 
(i.e., inclusion criteria of “at-risk,” elevated symptoms, depressive diagnosis). Of the 23 
controlled psychosocial treatments, 3 were determined to be prevention regimens with a mean 
ES of 0.17 (95% CI −0.17–0.52). There were 15 treatments based on depressive symptomatology 
that yielded an average ES of 0.81 (95% CI 0.49–1.11), whereas the remaining five treatments 
purported to address a diagnosis of Major Depressive Disorder and produced a mean ES of 0.84 
(95% CI 0.29–1.38). 
 
In terms of the 15 pre/post psychosocial interventions, 12 of the treatments focused on 
depressive diagnoses, 3 interventions targeted depressive symptomatology, and none were coded 
as prevention treatments. The pre-/posttreatments for Major Depressive Disorder produced a 
mean ES of 1.32 (95% CI 0.91–1.73), and the symptomatology-based interventions yielded an 
average ES of 0.72 (95% CI −0.21–1.66). 
 
3.3. Main effects: pharmacological studies 
Summary data for the pharmacological studies are presented in Table 2. The overall mean ES of 
the pharmacological studies at posttreatment was 0.19 (range −0.88–1.19; 95% CI −0.08–0.45). 
Follow-up data were not reported in the pharmacological studies. 
 
3.4. Interaction of age and outcome 
In order to facilitate a useful analysis of the potential interaction of age and treatment outcome, a 
false dichotomy was created whereby child studies were defined as having a mean age of 12 or 
younger and adolescent studies were characterized by a sample with a mean age of 13 or older 
(e.g., Emslie and Weisz; see Table 3). In the nine controlled psychosocial child studies, the mean 
ES was 0.65 (95% CI 0.34–0.95). In contrast, the five controlled adolescent studies yielded an 
average ES of 0.93 (95% CI 0.36–1.49). In regards to pre/post psychosocial studies, the mean ES 
for child samples was 0.73 (95% CI 0.14–1.30), whereas the mean ES for the six adolescent 
studies was 1.35 (95% CI 0.83–1.85). 
 
Table 3. Mean effect sizes based on average age and sex of sample 
 
 
With regard to the pharmacological trials, there were six studies in which the average age was 12 
or younger, seven studies in which the average age was 13 or older, and one study in which the 
ages ranged from 7 to 17 (Emslie et al., 1997). However, the authors stratified the sample by age 
(≤12 and ≥13) and reported no differences in outcome based on age. Therefore, age by treatment 
outcome data from this study was included in the child and adolescent analyses. For child 
pharmacotherapy trials, the mean ES was 0.15 (95% CI−0.12–0.42), whereas adolescent 
pharmacological studies yielded a mean ES of 0.28 (95% CI −0.24–0.79). 
 
3.5. Interaction of sex and outcome 
As shown in Table 3, when the data from psychosocial studies were analyzed by calculating ESs 
using different percentages of female subjects as criteria, there were some noteworthy findings. 
When the percentage of female subjects in controlled studies was 60% or greater (i.e., the 
majority), the mean ES was 0.90 (n=9; 95% CI 0.42–1.38), as compared to an ES of 0.63 (n=6; 
95% CI 0.32–0.92) when the percentage of female subjects was below 60%. Similarly, in 
pre/post studies, when the percentage of female subjects was 60% or greater, the average ES was 
1.20 (n=5; 95% CI 0.55–1.84), whereas the mean ES was 1.04 (n=4; 95% CI 0.56–1.51) when 
the percentage of female subjects dropped below 60%. 
 
3.6. Interaction of quality of study and outcome 
The standard mean difference ES estimates were cross-tabulated with the overall validity ratings 
for each psychosocial study. The average ES for studies based on the assessment of quality were 
as follows: unacceptable (0.47), inferior (0.85), fair (0.73), good (1.33), and excellent (1.64). 
Further, a correlation coefficient was computed to determine the relationship between the quality 
of the study and the average ES and yielded a statistically significant positive correlation (.67, 
P<.0001), indicating that as the quality of study increased, so did the average ES. 
 
4. Discussion 
The three research questions that were posed in this investigation addressed: (1) the overall 
efficacy of psychosocial interventions for child and adolescent depression; (2) the overall 
efficacy of pharmacological treatments for child and adolescent depression; and (3) whether 
there was evidence of differential efficacy for psychosocial and pharmacological treatments 
when age, sex, and quality of study were considered. The results of this comprehensive review 
indicate that overall, psychosocial treatments for early-onset depression lead to a substantial 
reduction in depressive symptoms in children and adolescents regardless of whether the 
experimental design was a between- or within-group study. The overall mean difference ES for 
controlled studies (0.72) indicates that the average child who received treatment for depression 
was better off than approximately 76% of the children who did not. According to Cohen's (1988) 
guidelines for interpreting the magnitude of ESs, an ES of 0.72 would be considered to be in the 
upper end of the “moderate” range [ES between 0.20 and 0.49 (small); ES between 0.50 and 0.79 
(moderate); ES of 0.80 or greater (large)]. Furthermore, the treatment effects were durable over a 
brief period of time (median=6.5 weeks). These findings mirror global reviews of psychotherapy 
with children whereby the treated youngsters fared much better than wait-list or no-treatment 
control subjects at posttreatment and follow-up (Casey; Kazdin; Weisz and Weisz). These data 
were also convergent with the findings from more circumscribed meta-analytic reviews that 
support the efficacy of social skills interventions for depressed youth (Black-Cecchini, 1996), 
cognitive–behavioral therapy for adolescents (Reinecke, M.A., Ryan, M.A. and DuBois, D.L., 
1998. Cognitive–behavioral therapy of depression and depressive symptoms during adolescence: 
a review and meta-analysis. Journal of the American Academy of Child and Adolescent 
Psychiatry 37, pp. 26–34. Abstract | Full Text via CrossRef | View Record in Scopus | Cited By 
in Scopus (124)Reinecke et al., 1998), and a smaller sample of depression treatments (Weisz et 
al., 1995). 
 
In regard to the pre/post psychosocial studies, the overall mean ES at posttreatment was 1.14, 
indicating that the treated subjects experienced significant reductions in depression at 
posttreatment. These findings were also durable over time (median=36 weeks), with a mean ES 
of 1.26 for the studies in which follow-up data were reported. The overall mean ES for controlled 
studies using intrasubject variance estimates was 1.23, similar to the mean ES for pre/post 
studies (1.14). 
 
Given these roughly commensurate values, a case could be made that the treatments in pre/post 
studies led to equally substantial reductions in depressive symptoms despite the methodological 
limitation of not having wait-list or no-treatment control group comparisons. Therefore, although 
the overall ES for pre/post studies was inflated because there were no wait-list or control group 
comparisons, the similar pre/post values across methodological designs augment the overall 
findings that psychosocial interventions are effective in the treatment of child and adolescent 
depression. Moreover, it appears that psychosocial interventions for depressed youth were 
effective regardless of whether the children were treated based on depressive symptomatology or 
a diagnosis of Major Depressive Disorder. In contrast, the mean ES of the controlled prevention 
studies was substantially lower. This finding was expected, based on the intuitive assumption 
that the children in at-risk studies were less depressed than the subjects in symptom- or 
diagnosis-based trials. Further, in prevention studies, the failure to detect elevated levels of 
depression is not only expected, but it is an artifact of measurement limitations (i.e., floor effect, 
limited sensitivity to low levels of depression). The lack of treatment effect in prevention studies 
does not diminish their importance. Indeed, it is difficult to assess when something did not 
happen! At the same time, it illustrates the need to follow at-risk samples longitudinally in 
comparison to no-treatment controls. 
 
With respect to pharmacological treatments, the results of this meta-analytic review indicate that 
in general, pharmacotherapy did not lead to a substantial reduction in depressive symptoms in 
children and adolescents. The overall mean ES at posttreatment was 0.19, suggesting that the 
average subject who was administered the active medication moved to the 58th percentile in the 
distribution of subjects who took a pharmacologically inert placebo. It is unclear whether these 
effects were maintained over time as follow-up data were not reported in the pharmacological 
studies. Further, the average placebo response rate across all of the studies was high (43%; range 
17–68%), indicating that much of derived benefits from pharmacotherapy were produced by the 
children's expectations of the treatment as opposed to the active medication itself. 
 
In comparison to the only other meta-analytic review located on the efficacy pharmacotherapy 
for depressed youth (Hazell et al., 1995), these findings were somewhat more discouraging but 
roughly commensurate, suggesting that antidepressant medications are not substantially superior 
to placebo in treating depressed youth. This is in contrast to finding that psychotropic 
medications are efficacious with adult populations (e.g., Elkin, 1994). 
 
However, a number of important points must be made about the interpretation of the 
pharmacological findings. First, as Conners (1992) aptly pointed out, “various methodological 
problems limit the conclusions” of pharmacological studies since there are substantial 
differences in the criteria for improvement, instrumentation, and selection procedures. Thus, in 
the present investigation, the pharmacological findings represent a synthesis of data that was 
based on potentially divergent definitions of “improvement” and differences in instrumentation. 
Nonetheless, these data certainly reveal some important trends about the efficacy of 
pharmacological treatments for depressed youth and the findings are congruent with most, if not 
all of the qualitative interpretations presented within each of the studies. Second, as a number of 
researchers have suggested (Anderson; Birmaher and Kye), firm conclusions about the efficacy 
of antidepressants in young people cannot be made until a larger body of literature is 
accumulated whereby some of the methodological limitations are addressed in future studies. 
Furthermore, of the 14 pharmacological studies included in the present analysis, only two 
controlled trials (14%) were located that utilized an SSRI (Emslie and Simeon). The vast 
majority of the trials (n=11) used TCAs (86%). Thus, the negative main effects regarding 
medication for depressed youth are attributable primarily to a lack of TCA efficacy, not 
necessarily pharmacotherapy overall. Although an ES of zero was entered in for the study 
conducted by Simeon et al. (1990) given the reported null findings and insufficient data to 
calculate an ES, the calculated ES for the study conducted by Emslie et al. (1997) was 0.59, 
indicating that the average treated subject (i.e., who took Prozac) was better off than 
approximately 72% of the subjects who took a placebo. Thus, it appears that there is some 
emerging evidence that SSRIs might be more effective than TCAs in treating child and 
adolescent mood disturbance. 
 
Results from the present investigation suggest that both psychosocial and pharmacological 
interventions were more effective for adolescents than for children. With psychosocial 
interventions, the mean ES for adolescent samples were higher than the mean ES for child 
samples, regardless of experimental design. Similarly, the interaction between age and 
pharmacotherapy indicated that medication was more effective for adolescents than for children. 
Indeed, the mean ES was almost twice as large for adolescents (0.28) than it was for children 
(0.15). Based on the descriptive data, the modal psychosocial treatment was cognitive–
behavioral therapy in group, individual, or family formats. Thus, the overall findings, which 
consist of a predominance of CBT interventions, might favor older subjects with the assumption 
that they have better developed cognitive skills and derive increased benefits from the 
cognitively oriented interventions (Weisz et al., 1995). With regard to the modest differential 
effects based on age in pharmacological studies, these findings might be attributable, in part, to 
the predominance of TCA trials and the empirical data that indicate that younger children may 
not respond favorably to TCAs since their noradrenergic systems are not fully developed until 
late adolescence and early adulthood (Murrin, Gibbens, & Ferrer, 1985). 
 
Psychosocial interventions for depression were somewhat more efficacious when the average 
percentage of female subjects was 60% or greater. These findings are consistent with the data 
from other reviews that lend support to the trend of differential efficacy in favor of female 
subjects (Casey and Weisz). However, these findings were far from compelling given the 
difficulties with coding and the magnitude of the difference between ES estimates. Nonetheless, 
more information is needed to better understand the relationship between sex and the treatment 
of child and adolescent depression, especially given that the female-to-male ratios for depressive 
illness begins to approximate the base rates for adult depressive disorders (i.e., approximately 
2:1) during middle to late adolescence. A possible explanation for the differential outcomes 
based on sex might be related to the fact that societal expectations, especially during 
adolescence, tend to promote more emotional expressiveness and awareness for females when 
compared to their male counterparts, which might, in turn, provide an advantage for girls and 
women in the context of most therapeutic regimes that tend to cherish these expectations (Weisz 
et al., 1995). 
 
In terms of the relationship between the quality of study and the mean ES for the psychosocial 
studies, it appears that as the quality increases, so does the mean ES. This finding was contrary to 
the hypothesis proposed by Wilson and Rachman (1983), but consistent with the findings 
reported by Weiss and Wiesz (1990). Therefore, these data provide evidence that methodological 
factors should be carefully considered during the development and implementation of 
experimental treatments for child and adolescent depression. At the same time, it appears less 
likely that studies with more limited controls will dangerously skew the findings. 
 
The clinical implications of these findings suggest that there are a number of controlled studies 
with mostly nonreferred children and adolescents suffering from depressive symptoms, who 
derive substantial benefit from school-based interventions. Moreover, there are a large number of 
pre/post studies with predominantly clinically referred children and adolescents suffering from 
depressive diagnoses, who benefit greatly from outpatient treatments. Thus, given the recent 
emphasis in the literature (e.g., Clarke and Hoagwood) regarding the application and 
generalization of lab studies (efficacy trials) to naturalistic clinical settings (effectiveness 
research), the implications of combining the roughly commensurate outcome findings (i.e., 
controlled and pre/post ES estimates) across study types are promising since these data are not 
simply based on analogue samples or mildly depressed youth. Finally, given the data regarding 
the effectiveness of psychosocial interventions, coupled with the paucity of findings to support 
pharmacotherapy for depressed youth, clinicians should consider psychosocial treatments to be 
first-line interventions until there are more definitive answers regarding the efficacy and safety 
of antidepressant medications for treating child and adolescent depression. Furthermore, 
although it is true that recent results from pharmacological trials have shown increased efficacy 
(e.g., Emslie et al., 1997), one should remain mindful of the fact that psychosocial interventions 
produce moderate to large treatment effects without the possibility of noxious side effects or an 
adverse impact on child development. 
 
Of course, the present findings must be considered in light of the limitations of the study. 
Perhaps the most compelling limitation of the present investigation is the fact that the vast 
majority of the 38 psychosocial and pharmacological studies (30; 79%) were published after 
1990. Thus, this is a relatively new and quickly expanding body of literature. As such, it was a 
challenge to keep up with all of the new developments regarding the treatment of child and 
adolescent depression and it is likely that some important findings were not included in the 
present analysis (i.e., “file drawer” problem). Another limitation is the fact that a number of 
important variables (e.g., age, sex, quality of study) could not be evaluated thoroughly or 
completely due to the limited information contained in the articles. Thus, it was not possible to 
make firm conclusions regarding the interaction between these variables and treatment outcome. 
 
Given the overall findings and these limitations, there are several important recommendations 
regarding future empirical efforts to investigate the effectiveness of treatments for child and 
adolescent depression. First, future researchers should explicitly report findings based on age and 
sex, in light of the limited interactional data that could be obtained regarding these important 
variables. Second, more consistent “improvement” criteria should be developed for 
pharmacological trials to facilitate more useful comparisons across studies. Third, researchers 
should attend closely to methodological variables when developing future outcome trials given 
the positive correlation between experimental rigor and ES. Finally, similar to adult studies, large 
controlled clinical trials examining the efficacy of psychotherapy and medication for child and 
adolescent depression should be developed and implemented to provide additional insights into 
this vital health-care issue. 
 
In sum, there is substantial evidence that child and adolescent depression is prevalent, persistent, 
and leads to a number of negative outcomes. However, it appears that there are a number of 
effective treatments that should be implemented expeditiously to ease the suffering of a 
considerable number of young people. 
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